FDA warns Noah Medical of San Jose, CA over quality system failures and missed injury reports for its Galaxy bronchoscopes.
What happened
FDA inspected Noah Medical's San Jose, CA facility from October 28 to November 26, 2024 and reviewed complaint and CAPA records. Investigators found the company did not properly investigate complaints, including cases of patient bleeding, a pneumothorax, and a death, and did not find root causes in several corrective action records. FDA also found the company failed to report two patient injuries to FDA within the required 30 days, one of which was never reported.
What FDA found
The company's corrective and preventive action (CAPA) procedure was not followed well enough to find root causes in 2 of 17 records reviewed, including one about biopsy tools that could not pass through the scope channel.
21 CFR 820.100(a)Complaint investigations were incomplete: the company did not look into camera image loss, scope kinks, bleeding and a collapsed lung, did not review batch records for an injured patient, and made no effort to get more information on a reported death.
21 CFR 820.198(a)Design validation was incomplete: biopsy tool passage was tested with only one tool in one scope configuration, and product sterility was not tested in shelf-life studies even though the scopes are sold sterile with a two-year expiration date.
21 CFR 820.30The company did not investigate root causes for bronchoscopes that failed leak tests or had kinked channels, and did not issue a supplier corrective action request.
21 CFR 820.90(a)Rework records did not document whether reworking the device had any adverse effect on the product.
21 CFR 820.90(b)(2)The company did not report two patient injuries to FDA within 30 calendar days; one report was never submitted and the other arrived about six months late.
21 CFR 803.50(a)(1)The written medical device reporting procedure omits key definitions, which could lead to wrong decisions about whether a complaint must be reported.
21 CFR 803.17(a)(1)
What FDA wants
FDA wants a written response within 15 business days describing the specific steps taken, documentation of systemic corrective actions, and a timetable for any work still ongoing. The reply must go to cdrhenforcement@fda.hhs.gov with CMS case #702414 in the subject line.
Who should pay attention
- hospitals and physicians using robotic bronchoscopy systems
- companies buying sterile-packaged scopes from contract manufacturers
- device makers that depend on suppliers for working-channel components
This is a summary. Read the original letter on fda.gov.